ATE418545T1 - Nnrt-inhibitoren - Google Patents

Nnrt-inhibitoren

Info

Publication number
ATE418545T1
ATE418545T1 AT06793671T AT06793671T ATE418545T1 AT E418545 T1 ATE418545 T1 AT E418545T1 AT 06793671 T AT06793671 T AT 06793671T AT 06793671 T AT06793671 T AT 06793671T AT E418545 T1 ATE418545 T1 AT E418545T1
Authority
AT
Austria
Prior art keywords
nnrt
inhibitors
nnrt inhibitors
Prior art date
Application number
AT06793671T
Other languages
German (de)
English (en)
Inventor
Yoshihito David Saito
Mark Smith
Zachary Kevin Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE418545T1 publication Critical patent/ATE418545T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/04—Six-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT06793671T 2005-09-30 2006-09-20 Nnrt-inhibitoren ATE418545T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72233505P 2005-09-30 2005-09-30

Publications (1)

Publication Number Publication Date
ATE418545T1 true ATE418545T1 (de) 2009-01-15

Family

ID=37685915

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06793671T ATE418545T1 (de) 2005-09-30 2006-09-20 Nnrt-inhibitoren

Country Status (15)

Country Link
US (1) US7625897B2 (pt)
EP (1) EP1937651B1 (pt)
JP (1) JP2009510013A (pt)
KR (1) KR20080064957A (pt)
CN (1) CN101273020A (pt)
AR (1) AR055666A1 (pt)
AT (1) ATE418545T1 (pt)
AU (1) AU2006298853A1 (pt)
BR (1) BRPI0617205A2 (pt)
CA (1) CA2623728A1 (pt)
DE (1) DE602006004473D1 (pt)
ES (1) ES2317584T3 (pt)
IL (1) IL190081A0 (pt)
TW (1) TW200800923A (pt)
WO (1) WO2007039463A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834178B2 (en) * 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
DE602007013573D1 (de) * 2006-08-16 2011-05-12 Hoffmann La Roche Nicht-nukleosidische reverse-transkriptase-hemmer
BRPI0811645A2 (pt) * 2007-05-30 2014-11-11 Hoffmann La Roche Inibidores de transcriptase reversa de não-nucleosídeo
WO2009000663A1 (en) * 2007-06-22 2008-12-31 F. Hoffmann-La Roche Ag Urea and carbamate derivatives as non-nucleoside reverse transcriptase inhibitors
AU2008340422B2 (en) * 2007-12-21 2014-06-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
KR20110094352A (ko) * 2008-12-22 2011-08-23 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225666A1 (en) 1995-06-30 1997-01-23 Smithkline Beecham Corporation Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
CA2205757C (en) * 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
WO2004085406A1 (en) * 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
EP1730120A1 (en) * 2004-03-23 2006-12-13 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
DE602006004473D1 (de) 2009-02-05
JP2009510013A (ja) 2009-03-12
IL190081A0 (en) 2008-08-07
ES2317584T3 (es) 2009-04-16
BRPI0617205A2 (pt) 2011-07-19
CA2623728A1 (en) 2007-04-12
CN101273020A (zh) 2008-09-24
TW200800923A (en) 2008-01-01
US20070078128A1 (en) 2007-04-05
WO2007039463A1 (en) 2007-04-12
EP1937651B1 (en) 2008-12-24
AU2006298853A1 (en) 2007-04-12
EP1937651A1 (en) 2008-07-02
AR055666A1 (es) 2007-08-29
KR20080064957A (ko) 2008-07-10
US7625897B2 (en) 2009-12-01

Similar Documents

Publication Publication Date Title
FR21C1019I2 (fr) Inhibiteurs de kinase de type biaryl-meta-pyrimidine
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
NO20076678L (no) Glutamataggrekanaseinhibitorer
LTPA2017010I1 (lt) Proteazomos inhibitoriai
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
EP1973889A4 (en) Cetp inhibitors
EP1971595A4 (en) CETP INHIBITORS
NO2017044I1 (no) iksekizumab
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
DK1979356T3 (da) Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer
DK1962830T3 (da) Azaindolhæmmere af aurorakinaser.
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
BRPI0719204A2 (pt) Inibidores de hdac
PT1586571E (pt) Inibidores da dipeptidil-peptidase
DK2253614T3 (da) IAP-inhibitorer
DK1778718T3 (da) Iap-inhibitorer
DK1934236T3 (da) Heterobifunktionelle pan-selektininhibitorer
EP2043672A4 (en) SELECTIVE INHIBITORS OF CASPASES
DK2066662T3 (da) Serinhydrolaseinhibitorer
IL190081A0 (en) Nnrt inhibitors
ATE493403T1 (de) Kinaseinhibitoren
EP2177529A4 (en) NEW SECRETASE HEMMER
EP1921078A4 (en) Multikinase inhibitor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties